A LinkedIn post from Forge Biologics highlights that the company is recruiting a Scientist II for upstream process development focused on adeno-associated virus, or AAV, gene therapy manufacturing. The role is described as a senior technical position with responsibilities spanning experimental design, scale-up strategy, and support for technology transfer and validation under cGMP conditions.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post suggests that Forge is continuing to invest in specialized talent to strengthen its process development and manufacturing capabilities for client gene therapy programs. For investors, this hiring activity may signal ongoing demand for the company’s CDMO services and an emphasis on building robust, scalable production platforms, which could support revenue growth and reinforce Forge’s competitive position in the AAV manufacturing segment.